A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anaemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anaemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 May 2017

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 08 Feb 2016 Results published in the Journal of Clinical Oncology
    • 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as report4ed by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top